Corify Care Receives FDA

Corify Care Receives FDA Clearance for ACORYS® — Introducing Instant, 4-D Electroanatomical Cardiac Mapping in Real-time

April 17, 2026
4:49 pm

MADRID, April 17, 2026 /PRNewswire/ -- Corify Care today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the ACORYS® System, the first imageless, non-invasive cardiac mapping platform capable of delivering a global, four-chamber view of cardiac electrical activity in real-time.

This milestone marks a fundamental shift in electrophysiology. By combining high-resolution 3D anatomical models with real-time electrical activity, the ACORYS^® System introduces true 4D cardiac mapping. This instant, whole-heart functional insight enables faster, safer, and more predictable ablation procedures.

Designed to complement modern EP workflows, ACORYS empowers physicians with real-time, panoramic mapping of complex arrhythmia mechanisms. This approach allows clinical teams to gain immediate functional insight without the need for pre-procedural imaging or the induction of unstable arrhythmias.

Corify Care Receives FDA Clearance for ACORYS® — Introducing Instant, 4-D Electroanatomical Cardiac Mapping in Real-time

Sign up for Blog Updates